These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 18387063

  • 1. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
    Xie X, Vondeling H.
    Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, Valentine WJ, Palmer AJ.
    Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [Abstract] [Full Text] [Related]

  • 3. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ, Tucker DM.
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [Abstract] [Full Text] [Related]

  • 4. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
    Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, Stratton I, Holman R, UKPDS Group. United Kingdom Prospective Diabetes Study.
    Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
    [Abstract] [Full Text] [Related]

  • 6. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes.
    Palmer AJ, Sendi PP, Spinas GA.
    Schweiz Med Wochenschr; 2000 Jul 11; 130(27-28):1034-40. PubMed ID: 10953853
    [Abstract] [Full Text] [Related]

  • 7. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.
    Diabet Med; 2015 Jul 11; 32(7):890-8. PubMed ID: 25817050
    [Abstract] [Full Text] [Related]

  • 8. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S.
    Appl Health Econ Health Policy; 2016 Jun 11; 14(3):281-92. PubMed ID: 26961276
    [Abstract] [Full Text] [Related]

  • 9. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL, Willis WD, Foos V.
    Curr Med Res Opin; 2010 Jan 11; 26(1):163-75. PubMed ID: 19919377
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D, Calado F, Gruenberger JB, Ong SH, Carvalho D, Silva-Nunes J, Johal S, Viana R.
    J Med Econ; 2014 Jul 11; 17(7):499-507. PubMed ID: 24708176
    [Abstract] [Full Text] [Related]

  • 11. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
    Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR, UKPDS 72 United Kingdom Prospective Diabetes Study.
    Diabetologia; 2005 May 11; 48(5):868-77. PubMed ID: 15834550
    [Abstract] [Full Text] [Related]

  • 12. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N.
    Clin Drug Investig; 2016 Aug 11; 36(8):649-59. PubMed ID: 27221806
    [Abstract] [Full Text] [Related]

  • 13. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.
    Pharmacoeconomics; 2006 Aug 11; 24 Suppl 1():49-59. PubMed ID: 16800162
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K, Persson U.
    J Med Econ; 2014 Sep 11; 17(9):658-69. PubMed ID: 24950434
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
    Cai X, Shi L, Yang W, Gu S, Chen Y, Nie L, Ji L.
    J Med Econ; 2019 Apr 11; 22(4):336-343. PubMed ID: 30663458
    [Abstract] [Full Text] [Related]

  • 16. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC, Samyshkin Y, Langer J, Palmer JL.
    J Med Econ; 2012 Apr 11; 15 Suppl 2():28-37. PubMed ID: 22834986
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R.
    BMC Health Serv Res; 2018 Feb 01; 18(1):78. PubMed ID: 29391064
    [Abstract] [Full Text] [Related]

  • 18. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
    Tunis SL, Minshall ME.
    Curr Med Res Opin; 2010 Jan 01; 26(1):151-62. PubMed ID: 19919376
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.
    BMC Health Serv Res; 2015 Nov 05; 15():496. PubMed ID: 26541516
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
    Neeser K, Lübben G, Siebert U, Schramm W.
    Pharmacoeconomics; 2004 Nov 05; 22(5):321-41. PubMed ID: 15061682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.